Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Encouraging early data from Parkinson disease trial reported
August 15th, 2005
Avigen, Inc., (AVGN) announced encouraging results from the first patient treated in a phase I/II clinical trial of AV201, the company's drug candidate for the treatment of mid- to later-stage Parkinson disease. The results from positron emission tomography (PET) brain scans obtained 6 months after AV201 infusion indicated an increased activity of the gene product, aromatic L-amino acid decarboxylase (AADC) in the targeted area of the brain, compared with the patient's pre-treatment PET scans. These findings are consistent with increased dopamine production and transgene expression. In Parkinson disease, brain dopamine concentrations decline, causing...
Source: Pharma Business Week (2005-08-15)
|
